• RESEARCH

    Real-world data on HER2-positive metastatic CRC from 14 Japanese centers

    A multicenter retrospective study of 45 patients with HER2-positive metastatic colorectal cancer diagnosed between 2010 and 2023 examined outcomes with different first-line targeted agents and assessed safety of trastuzumab plus pertuzumab. (International Journal of Clinical Oncology)